Remove tag china
article thumbnail

Cartherics grants licence for CTH-004 to Shunxi

Pharmaceutical Technology

Under the deal terms, Shunxi will have licence to develop, manufacture, and commercialise CTH-004 to treat several solid tumours including ovarian cancer in Greater China, including Hong Kong, Taiwan, Mainland China, and Macao. Shunxi will also hold an option to negotiate rights to other CAR-T products, which include the licenced IP.

article thumbnail

STAT+: This billionaire has quietly driven Boston’s biotech industry for decades

STAT News

Among the small bunch of billionaires that the local biotech industry has created, Tim Springer may be the only one who regularly rides his bike to work in the Longwood Medical Area, where his ID tag identifies him simply as a “staff scientist.”

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Global (68M) cardiomyopathies market projected to grow to $9.63bn by 2031

Pharmaceutical Technology

The US is set to dominate the cardiomyopathy landscape because of the country’s high prevalence of dilated cardiomyopathy (DCM) relative to the other markets in the 7MM, as well as the higher price tag on US-marketed therapeutics. The second highest contributing market is APAC, generating 33.2%

Marketing 130
article thumbnail

Cannabinoids receptors: popular preclinical target but banned in 137 countries

Pharmaceutical Technology

Collectively, cannabinoid receptors (CB1 and CB2) are currently the most popular targets in preclinical stage of development, with 391 drugs tagged in total. This is closely followed by CB2 receptors in second place. This is followed by epilepsy at 8% of the pipeline and multiple sclerosis at 7% of the pipeline.

article thumbnail

Anti-Counterfeiting Technologies in Healthcare

Roots Analysis

Examples of such technologies include DNA Taggants (a unique DNA tag used in the product / packaging that can be scanned using a designated instrument / equipment), invisible printing technologies, digital watermark technologies and hidden markers / print technologies.

article thumbnail

FDA gives AbbVie’s c-Met lung cancer ADC a breakthrough tag

pharmaphorum

Novartis’ Tepmetko (tepotinib) was approved b the FDA last year for both treatment naĂŻve and previously treated METex14 positive NSCLC patients, as was Merck’s Tabrecta (capmatinib), while Hutchmed’s Orpathys (savolitinib) has been approved as a second-line option in China.

Antibody 111
article thumbnail

A broad range of unmet needs remains in the immuno-oncology space

Pharmaceutical Technology

High-prescribing physicians surveyed by GlobalData across eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China) identified a broad range of unmet needs in the IO space (see Figure 1). Despite the significant advances that have been made in the IO field, a huge level of unmet need remains.